Brief: Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
16/05/2024 13:41
May 16 (Reuters) - Avenue Therapeutics Inc ATXI.O :
* AVENUE THERAPEUTICS INC - ANNOUNCED COMPLETION OF LAST
PATIENT'S
FINAL VISIT IN COMPANY'S PHASE 1B/2A CLINICAL TRIAL OF AJ201
* AVENUE THERAPEUTICS INC - TOPLINE DATA ARE EXPECTED TO BE
REPORTED MID-YEAR 2024
Source text for Eikon: ID:nGNX8t6mjd
Further company coverage: ATXI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Avenue Therapeutics
See all newsBrief: Axsome Therapeutics Acquires AZD7325, A Selective GABA-A Modulator For Treatment Of Epilepsy
Avenue Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Avenue Therapeutics Annji Intends To Terminate License Agreement With Co
Brief: Avenue Therapeutics Receives Delist Letter From Nasdaq Under Nasdaq Listing Rule 5550(B)(1)
Avenue Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary